COVID-19 infection is a multi-system clinical disorder that was associated with increased morbidity and mortality. Even though antiviral therapies such as Remdesvir offered modest efficacy in reducing the mortality and morbidity, they were not efficacious in reducing the risk of future infections. So, FDA approved COVID-19 vaccines which are widely administered in the general population worldwide. These COVID-19 vaccines offered a safety net against future infections and re-infections. Most of these vaccines contain inactivated virus or spike protein mRNA that are primarily responsible for inducing innate and adaptive immunity. These vaccines were also formulated to contain supplementary adjuvants that are beneficial in boosting the immune response. During the pandemic, clinicians all over the world witnessed an uprise in the incidence and prevalence of cardiovascular diseases (COVID-Heart Syndrome) in patients with and without cardiovascular risk factors. Clinical researchers were not certain about the underlying reason for the upsurge of cardiovascular disorders with some blaming them on COVID-19 infections while others blaming them on COVID-19 vaccines. Based on the literature review, we hypothesize that adjuvants included in the COVID-19 vaccines are the real culprits for causation of cardiovascular disorders. Operation of various pathological signaling events under the influence of these adjuvants including autoimmunity, bystander effect, direct toxicity, anti-phospholipid syndrome (APS), anaphylaxis, hypersensitivity, genetic susceptibility, epitope spreading, and anti-idiotypic antibodies were partially responsible for stirring up the onset of cardiovascular disorders. With these mechanisms in place, a minor contribution from COVID-19 virus itself cannot be ruled out. With that being said, we strongly advocate for careful selection of vaccine adjuvants included in COVID-19 vaccines so that future adverse cardiac disorders can be averted.
Clin Exp Dermatol. 2001 Jul;26(5):427-33
[PMID:
11488833]
Egypt Heart J. 2021 Jan 05;73(1):2
[PMID:
33400005]
J Inorg Biochem. 2005 Sep;99(9):1895-8
[PMID:
15961160]
PLoS Med. 2022 Feb 22;19(2):e1003926
[PMID:
35192597]
Curr Opin Immunol. 2010 Jun;22(3):411-6
[PMID:
20466528]
Immunotherapy. 2014;6(10):1055-71
[PMID:
25428645]
J Immunol. 2008 Oct 1;181(7):4807-14
[PMID:
18802084]
Clin Exp Immunol. 2004 Jul;137(1):59-64
[PMID:
15196244]
Circ Res. 2021 Apr 16;128(8):1214-1236
[PMID:
33856918]
Vaccines (Basel). 2015 Apr 16;3(2):320-43
[PMID:
26343190]
Circulation. 2022 Sep 6;146(10):743-754
[PMID:
35993236]
Free Radic Biol Med. 2004 Feb 1;36(3):380-7
[PMID:
15036357]
Cell Immunol. 2011;271(2):438-49
[PMID:
21939961]
Nat Immunol. 2008 Aug;9(8):847-56
[PMID:
18604214]
Nat Rev Drug Discov. 2021 Jun;20(6):454-475
[PMID:
33824489]
PLoS Pathog. 2008 Aug 29;4(8):e1000138
[PMID:
18769719]
JAMA. 2021 Oct 12;326(14):1390-1399
[PMID:
34477808]
PLoS One. 2012;7(3):e33723
[PMID:
22470463]
Lancet. 1983 Oct 8;2(8354):824-6
[PMID:
6137652]
J Immunol. 2000 Feb 1;164(3):1617-24
[PMID:
10640783]
Immunol Res. 2013 Mar;55(1-3):83-90
[PMID:
22983897]
Science. 1996 Jun 28;272(5270):1947-50
[PMID:
8658169]
Lupus. 2012 Feb;21(2):195-202
[PMID:
22235053]
JAMA Netw Open. 2023 Mar 1;6(3):e232598
[PMID:
36920396]
Curr Opin Immunol. 2008 Aug;20(4):383-8
[PMID:
18573338]
J Invest Dermatol. 1998 Feb;110(2):103-9
[PMID:
9457902]
Psychiatry Investig. 2015 Jul;12(3):417-9
[PMID:
26207140]
Clin Exp Immunol. 1987 Sep;69(3):566-74
[PMID:
3665185]
Int Arch Allergy Immunol. 2014;164(3):171-7
[PMID:
25033972]
Med J Aust. 2019 Aug;211(4):184-188
[PMID:
31271468]
J Exp Med. 1995 Mar 1;181(3):1123-31
[PMID:
7869033]
Curr Med Chem. 2011;18(17):2630-7
[PMID:
21568886]
J Virol. 2001 Dec;75(24):12421-30
[PMID:
11711632]
Arthritis Rheum. 2004 Jan;50(1):297-304
[PMID:
14730628]
Lupus. 2012 Jun;21(7):711-4
[PMID:
22635209]
PLoS One. 2012;7(3):e33536
[PMID:
22470453]
J Postgrad Med. 2014 Jul-Sep;60(3):309-17
[PMID:
25121375]
Trends Immunol. 2010 Mar;31(3):103-9
[PMID:
20153253]
Indian Heart J. 2023 Jul-Aug;75(4):217-223
[PMID:
37399904]
Adv Exp Med Biol. 2017;1003:187-221
[PMID:
28667560]
J Virol. 2015 Mar;89(6):2995-3007
[PMID:
25520500]
Health Promot Perspect. 2021 Dec 19;11(4):467-475
[PMID:
35079592]
Vaccines (Basel). 2023 Apr 26;11(5):
[PMID:
37243006]
J Autoimmun. 2001 May;16(3):175-86
[PMID:
11334481]
Arthritis Rheum. 2002 Apr;46(4):1019-27
[PMID:
11953980]
PLoS One. 2012;7(7):e40745
[PMID:
22829882]
Vaccine. 2013 Nov 4;31(46):5300-5
[PMID:
23727002]
J Autoimmun. 2003 Aug;21(1):17-26
[PMID:
12892732]
Front Immunol. 2018 Apr 17;9:779
[PMID:
29719538]
J Exp Med. 2006 Jul 10;203(7):1685-91
[PMID:
16818675]
Drug Saf. 2015 Nov;38(11):1059-74
[PMID:
26446142]
Rev Med Virol. 2005 Jan-Feb;15(1):17-27
[PMID:
15386590]
Biochem Biophys Res Commun. 1999 Jun 7;259(2):255-61
[PMID:
10362496]
Nat Rev Dis Primers. 2018 Jan 25;4:18005
[PMID:
29368699]
J Inorg Biochem. 2018 Apr;181:96-103
[PMID:
29221615]
Eur J Clin Nutr. 2020 Jun;74(6):852-855
[PMID:
32371988]
J Autoimmun. 2013 Dec;47:1-16
[PMID:
24238833]
Am Heart J. 1990 Jun;119(6):1322-8
[PMID:
2162138]
Autoimmun Rev. 2016 Jul;15(7):644-8
[PMID:
26903475]
Lupus. 2009 Nov;18(13):1217-25
[PMID:
19880572]
Pharmacol Res. 2015 Oct;100:190-209
[PMID:
26275795]
World J Clin Cases. 2022 Sep 26;10(27):9556-9572
[PMID:
36186196]
Nat Med. 2023 Jan;29(1):219-225
[PMID:
36658423]
Int J Environ Res Public Health. 2022 Jan 19;19(3):
[PMID:
35162128]
Innate Immun. 2012 Apr;18(2):333-42
[PMID:
21926163]
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
[PMID:
29326426]
Cell. 1987 Sep 11;50(6):819-20
[PMID:
3621346]
J Invest Dermatol. 2005 Oct;125(4):629-37
[PMID:
16185260]
Nat Med. 1998 Jul;4(7):781-5
[PMID:
9662368]
Rheumatology (Oxford). 2006 Oct;45 Suppl 4:iv8-13
[PMID:
16980725]
Front Endocrinol (Lausanne). 2017 Jan 24;7:150
[PMID:
28167927]
PLoS One. 2012;7(4):e35421
[PMID:
22536382]
Vaccine. 2014 Nov 12;32(48):6377-89
[PMID:
24975812]
Autoimmunity. 2001;34(3):199-204
[PMID:
11908778]
Cell. 2020 Oct 15;183(2):290-295
[PMID:
33064982]
Autoimmun Rev. 2010 Jul;9(9):631-3
[PMID:
20478412]
PLoS Pathog. 2014 Jan;10(1):e1003875
[PMID:
24465206]
Can J Cardiol. 2021 May;37(5):722-732
[PMID:
33212203]
Nat Med. 2013 Dec;19(12):1597-608
[PMID:
24309663]
Nat Rev Immunol. 2008 Apr;8(4):279-89
[PMID:
18340345]
J Autoimmun. 2011 Feb;36(1):4-8
[PMID:
20708902]
Case Rep Cardiol. 2022 Apr 6;2022:9943937
[PMID:
35402051]
J Inorg Biochem. 2011 Nov;105(11):1489-99
[PMID:
22099159]
Nat Med. 2022 Mar;28(3):583-590
[PMID:
35132265]
Expert Rev Clin Immunol. 2013 Apr;9(4):361-73
[PMID:
23557271]
Cell Mol Life Sci. 2000 Apr;57(4):542-51
[PMID:
11130454]
Neth Heart J. 2021 May;29(5):273-279
[PMID:
33630274]
JAMA. 2022 Mar 22;327(12):1113-1114
[PMID:
35234824]
Vaccine. 2012 Mar 28;30(15):2556-63
[PMID:
22326642]
Front Immunol. 2019 May 10;10:941
[PMID:
31134062]
Lupus. 2012 Feb;21(2):223-30
[PMID:
22235057]
J Periodontal Res. 2016 Jun;51(3):381-94
[PMID:
26362417]
J Exp Med. 1999 Apr 5;189(7):1033-42
[PMID:
10190894]
Nat Rev Cardiol. 2020 Sep;17(9):543-558
[PMID:
32690910]
Nat Commun. 2021 Sep 14;12(1):5417
[PMID:
34521836]
